![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Laboratoire de Recherche en Biologie Vasculaire et Cellulaire, EA
1557, Université Paris 7, Hôpital Lariboisière,
Paris, France (C.R., O.C., M.-P.W., J.-L.W.),
Institut National de la
Santé et de la Recherche Médicale Unité 26, Hôpital Fernand Widal, Paris, France (C.R., J.-M.S.),
Berlex
Biosciences, Richmond, California 94804 (M.N., E.L., J.M., L.Z.), and
Department of Physiology, Medicine, and Surgery, Columbia University,
College of Physicians and Surgeons, New York 10032 (A.-M.S.)
Vascular dysfunction in patients with diabetes mellitus is related to
advanced glycation end product (AGE) formation. We previously showed
that AGEs produce an increase in vascular permeability and generated an
oxidant stress after binding to the receptor (RAGE) present on
endothelium. RAGE, a 35-kDa protein that belongs to the immunoglobulin
superfamily, has been cloned from a rat lung cDNA library, and
recombinant rat soluble RAGE (rR-RAGE) has been produced in insect
cells. The sequence of RAGE is highly conserved between human and rat.
We studied the biological effect of rR-RAGE and pharmacokinetics of
125I-rR-RAGE after intravenous or intraperitoneal
administration in normal and streptozotocin-induced diabetic rats.
rR-RAGE prevented albumin or inulin transfer through a bovine aortic
endothelial cell monolayer, restored the hyperpermeability observed in
diabetic rats or induced in normal rats by diabetic rat red blood
cells, and corrected the reactive oxygen intermediate production after intravenous or intraperitoneal administration. After intravenous injection of 125I-rR-RAGE, the distribution half-life was
longer (p 
0.01) in diabetic (0.15 and 4.01 hr) than in normal (0.02 and 0.21 hr) rats, as was the case for the
elimination half-lives (diabetic, 57.17 hr; normal, 26.02 hr;
p 0.01). Distribution volume was higher in
diabetic than in normal rats (6.94 and 3.24 liter/kg, respectively;
p = 0.049). Our study showed that rR-RAGE was
biologically active in vivo and slowly cleared, which
suggests it could be considered as a potential therapy.
This article has been cited by other articles:
|
|
 |
|
  M. A. Queisser, F. M. Kouri, M. Konigshoff, M. Wygrecka, U. Schubert, O. Eickelberg, and K. T. Preissner Loss of RAGE in Pulmonary Fibrosis: Molecular Relations to Functional Changes in Pulmonary Cell Types Am. J. Respir. Cell Mol. Biol., September 1, 2008; 39(3): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, S. Tasaka, Y. Shiraishi, K. Fukunaga, W. Yamada, H. Seki, Y. Ogawa, K. Miyamoto, Y. Nakano, N. Hasegawa, et al. Role of Soluble Receptor for Advanced Glycation End Products on Endotoxin-induced Lung Injury Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 356 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ohtaki, W. Kamitani, Y. Watanabe, Y. Hayashi, H. Yanai, K. Ikuta, and K. Tomonaga Downregulation of an Astrocyte-Derived Inflammatory Protein, S100B, Reduces Vascular Inflammatory Responses in Brains Persistently Infected with Borna Disease Virus J. Virol., June 1, 2007; 81(11): 5940 - 5948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Hanford, J. J. Enghild, Z. Valnickova, S. V. Petersen, L. M. Schaefer, T. M. Schaefer, T. A. Reinhart, and T. D. Oury Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE) J. Biol. Chem., November 26, 2004; 279(48): 50019 - 50024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chavakis, A. Bierhaus, N. Al-Fakhri, D. Schneider, S. Witte, T. Linn, M. Nagashima, J. Morser, B. Arnold, K. T. Preissner, et al. The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins: A Novel Pathway for Inflammatory Cell Recruitment J. Exp. Med., November 17, 2003; 198(10): 1507 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kaminski, J. A. Belperio, P. B. Bitterman, L. Chen, S. W. Chensue, A. M.K. Choi, S. Dacic, J. H. Dauber, R. M. du Bois, J. J. Enghild, et al. Idiopathic Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., September 1, 2003; 29(3): S1 - 105. [Full Text] [PDF]
|
|
|
|
 |
|
 M.-P. Wautier, O. Chappey, S. Corda, D. M. Stern, A. M. Schmidt, and J.-L. Wautier Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE Am J Physiol Endocrinol Metab, May 1, 2001; 280(5): E685 - E694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Kiuchi, J Nejima, T Takano, M Ohta, H Hashimoto, and G F BAXTER Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients Heart, January 1, 2001; 85(1): 87 - 91. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Renard, O. Chappey, M. P. Wautier, M. Nagashima, J. Morser, J. M. Scherrmann, and J. L. Wautier The Human and Rat Recombinant Receptors for Advanced Glycation End Products Have a High Degree of Homology but Different Pharmacokinetic Properties in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1458 - 1466. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
